SecBot SecBot
PREM14A ·Filed May 28, 2026

CPRX

CATALYST PHARMACEUTICALS, INC.
BULLISH
Impact 8/10
Horizonweeks Processed5mo ago SEC0001193125-26-245426
Preliminary proxy statement (merger-related)
Actionable Insight ▲ Bullish

The cash premium offers immediate realized value with high probability of closing given committed financing and no financing condition. Monitor the June 22 HSR deadline and shareholder vote timing. The 3.8% termination fee is below the 3-4% standard for mid-cap pharma, making a competing bid plausible but unlikely given the active market check process

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$31.23
T+0 close · May 28, 2026 · via day close
Latest settled
+0.74%
T+20 · $31.46
Vs SPY
+2.53%
α at T+20
Next horizon
T+60
due 3mo ago
  1. T+0 · May 29 $31.23entry
  2. T+1 · 6mo ago +0.13%α −0.15% · $31.27
  3. T+5 · 6mo ago +0.16%α +0.45% · $31.28
  4. T+20 · 5mo ago +0.74%α +2.53% · $31.46
  5. T+60 · due 3mo ago Pending
Loading chart...

Executive Summary

Catalyst Pharmaceuticals (CPRX) filed a preliminary proxy statement (PREM14A) seeking stockholder approval for its acquisition by Angelini Pharma at $31.50 per share in cash, a transaction valued at approximately $4.1 billion. The board unanimously recommends the deal, which includes a 28% premium to the 30-day VWAP and follows the resolution of all FIRDAPSE patent litigation with Hetero agreeing not to launch a generic before January 2035.

Key Financial Metrics

Deal Value
$4.1B
Premium
28%
Deal Type
merger

Key Facts

  • Merger consideration: $31.50 per share in cash (28% premium to 30-day VWAP, 21% premium to unaffected close of $25.94)
  • Total equity value: approximately $4.1 billion
  • Board unanimously recommends voting FOR the merger proposal
  • J.P. Morgan fairness opinion: consideration is fair from a financial point of view
  • All executive officers and directors (~10% of outstanding shares) have signed voting agreements to vote FOR the merger
  • HSR waiting period expires June 22, 2026; merger expected to close in Q3 2026
  • Termination fee: $155,475,048 (~3.8% of equity value)
  • Angelini Pharma has $3.99B in committed debt financing from BNP Paribas; financing is not a condition to closing
  • All outstanding in-the-money options and RSUs will vest and be cashed out at closing
  • No financing condition; $155M reverse termination fee if Catalyst accepts a superior proposal

Financial Impact

$4.1B total equity value at $31.50/share cash; 28% premium to 30-day VWAP

revenueepsdebtdilutioncash

Risk Factors

  • Shareholder vote required; unaffiliated holders must approve by majority of outstanding shares
  • HSR review could be extended by a Second Request
  • Pre-closing operating covenants restrict Catalyst from pursuing alternative transactions
  • Risk of stockholder litigation challenging the process or price

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
93% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
PREM14A Filing (Primary)0001193125-26-245426
Document: d76493dexfilingfees.htm0001193125-26-245426
Document: 0001193125-26-245426-index-headers.html0001193125-26-245426
Document: 0001193125-26-245426-index.html0001193125-26-245426
Document: 0001193125-26-245426.txt0001193125-26-245426

Track record

16 reports on CPRX

Performance horizon

3 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +25.72% at T+60 after the Feb 25, 2026 report. 5 of 8 went positive at some point.

Filters
  1. Nov 4, 202612d ago Institutional Cluster Bearish 4/10 No price data
  2. Aug 22, 202612w ago Institutional Cluster Mixed 5/10 No price data
  3. Jul 24, 202616w ago 15-12G Bearish 9/10 Entry $31.49 No price data
  4. Jul 17, 202617w ago EFFECT Bearish 5/10 Entry $31.49 No price data
  5. Jul 15, 202617w ago 25-NSE Bearish 9/10 Entry $31.49 No price data
  6. Jul 8, 202618w ago 8-K Bullish 6/10 Entry $31.47 No price data
  7. Jun 30, 202619w ago DEFA14A Neutral 3/10 Entry $31.44 No price data
  8. Jun 30, 202619w ago 8-K Neutral 4/10 Entry $31.44 No price data
  9. May 28, 202624w ago PREM14A Bullish 8/10 Viewing Entry $31.23 to $31.46 ▲ +0.74% +2.53% vs SPY
  10. May 12, 202626w ago DEFA14A Neutral 3/10 Entry $31.14 to $31.34 ▲ +0.64% +2.37% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens in 6h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 28, 2026